![]() | The role of proteasome inhibitors in the treatment of R/R multiple myeloma Süre: 1:59 | Boyut: 4.54 MB |
![]() | Updates in the treatment of R/R LBCL: promising novel agents in the pipeline Süre: 1:18 | Boyut: 2.98 MB |
![]() | The value of CAR-T cell therapy for the treatment of R/R multiple myeloma Süre: 2:00 | Boyut: 4.58 MB |
![]() | The growing importance of CELMoDs in the treatment of R/R multiple myeloma Süre: 1:59 | Boyut: 4.54 MB |
![]() | Insights into the efficacy of linvoseltamab in the treatment of R/R multiple myeloma Süre: 1:47 | Boyut: 4.08 MB |
![]() | Complications Compared to Expected Early Botox Effects in Treatment of R-CPD Süre: 11:11 | Boyut: 25.6 MB |
![]() | Real-world safety and efficacy of talquetamab for the treatment of R/R myeloma Süre: 1:47 | Boyut: 4.08 MB |
![]() | Safety and efficacy of golcadomide (CC-99282) in the treatment of R/R NHL Süre: 1:22 | Boyut: 3.13 MB |